Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003-2004). (Q46622789)

23 December 2017

title

Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003-2004). (English)

1 reference

23 December 2017

author name string

Fakhrzadeh H

1 reference

23 December 2017

Ghotbi S

1 reference

23 December 2017

Pourebrahim R

1 reference

23 December 2017

Heshmat R

1 reference

23 December 2017

Nouri M

1 reference

23 December 2017

Shafaee A

1 reference

23 December 2017

Larijani B

1 reference

23 December 2017

publication date

1 November 2005

1 reference

23 December 2017

Journal of Human Hypertension

published in

1 reference

23 December 2017

volume

1 reference

23 December 2017

issue

1 reference

23 December 2017

page(s)

869-876

1 reference

23 December 2017

Essential Hypertension : Part I: Definition and Etiology

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Relationship of homocysteine with cardiovascular disease and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Characterization of the stress-inducing effects of homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Hyperhomocyst(e)inemia Is a Risk Factor for Arterial Endothelial Dysfunction in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Total homocysteine and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Does homocysteine cause hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Epidemiology of blood pressure and predictors of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

High Homocysteine Levels Are Independently Related to Isolated Systolic Hypertension in Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine, hypertension and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Antihypertensive treatment and homocysteine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Folate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

5-Methyltetrahydrofolate, the Active Form of Folic Acid, Restores Endothelial Function in Familial Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Plasma Homocysteine, Aortic Stiffness, and Renal Function in Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Hyperhomocysteinemia and Atherosclerotic Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Homocysteine and Atherothrombosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Plasma homocysteine levels and mortality in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Homocysteine and cardiovascular disease: cause or effect?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001911

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001911

1 reference

23 December 2017

1 reference

23 December 2017